Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Cost of Revenue (2016 - 2025)

International Stem Cell (ISCO) has disclosed Cost of Revenue for 16 consecutive years, with $273000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Cost of Revenue fell 18.26% to $273000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $1.2 million, a 8.7% decrease, with the full-year FY2024 number at $1.2 million, down 2.41% from a year prior.
  • Cost of Revenue was $273000.0 for Q1 2025 at International Stem Cell, down from $288000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $2.0 million in Q4 2022 to a low of -$1.1 million in Q4 2023.
  • A 5-year average of $473823.5 and a median of $334000.0 in 2024 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 165.99% in 2022, then plummeted 154.83% in 2023.
  • International Stem Cell's Cost of Revenue stood at $735000.0 in 2021, then surged by 165.99% to $2.0 million in 2022, then tumbled by 154.83% to -$1.1 million in 2023, then soared by 126.87% to $288000.0 in 2024, then decreased by 5.21% to $273000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Cost of Revenue are $273000.0 (Q1 2025), $288000.0 (Q4 2024), and $292000.0 (Q3 2024).